James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

AMZN Stock: Amazon Inches Closer to Being a Reasonable Investment

AMZN stock may be overbought after Friday's post-earnings jump, but there's relatively good reason for bullishness

CI: What Cigna Stock Owners Need to Know About the Anthem Deal

If Cigna stock jumps on an official acquisition offer from Anthem, CI owners may want to take what they can get while they can still get it.

Why Freeport-McMoRan Inc (FCX), Caterpillar Inc. (CAT) and Dow Chemical Co (DOW) Are 3 of Today’s Worst Stocks

Freeport-McMoRan (FCX), Caterpillar (CAT) and Dow Chemical (DOW) were all driven lower by lousy earnings news, lousy outlooks or both.

One (Relatively) Good Quarter Doesn’t Make GM Stock Bulletproof

GM stock is up sharply following earnings news, but a longer-term look at the raw numbers makes the lack of growth clear.

Trade of the Day: Intercontinental Exchange (ICE) Moves Past the Tipping Point

Intercontinental Exchange (ICE) just quietly edged above a key near-term ceiling, spurred by support at a major long-term support line.

The Bears Aren’t Scared to Follow Through

Stocks take the same bearish turn they've taken several times already this year. Here's where they could end up, and where things could get really bad.

Why Apple (AAPL), Biogen (BIIB) and Illumina (ILMN) Are 3 of Today’s Worst Stocks

Shareholders of Apple (AAPL), Biogen (BIIB) and Illumina (ILMN) were on the losing side of the table on Wednesday, mostly thanks to earnings.

8 Dividend Stocks to Buy for Income Growth

Dividend stocks can be poor long-term investments if the per-share payout doesn't actually increase over time. With these stocks, that's no worry.

Did You Just Sell AAPL Stock? Here’s a Reality Check.

AAPL stock fell right on cue, even if for the wrong reason. Just don't expect the weakness to last.

Trade of the Day: Climb up American Tower (AMT)

American Tower (AMT) has broken out of a consolidation rut and is now clearing key hurdles.